|
Phenotype
|
EUR
|
Non-EUR
|
|---|
|
N
|
Affected patients, n (%)
|
N
|
Affected patients, n (%)
|
ORa (95% CI)
|
P valueb
|
|---|
|
Renal
|
320
|
75 (24.4%)
|
243
|
81 (33.3%)
|
1.60 (1.11–2.32)
|
0.01
|
|
Neurological
|
330
|
36 (10.9%)
|
244
|
42 (17.2%)
|
1.67 (1.05–2.74)
|
0.03
|
|
Haematological
|
366
|
185 (50.5%)
|
268
|
106 (39.6%)
|
0.65 (0.47–0.89)
|
0.007
|
|
dsDNA positivity
|
370
|
143 (38.6%)
|
270
|
83 (30.7%)
|
0.70 (0.51–0.98)
|
0.04
|
|
Admission ratec
|
351
|
140 (39.9%)
|
196
|
86 (43.9)
|
1.20 (0.84–1.71)
|
0.31
|
|
Biologics ever neededd
|
332
|
23 (6.9%)
|
239
|
12 (5.0%)
|
0.70 (0.34–1.43)
|
0.33
|
- Summary of available clinical history for the 656 study participants from cohort 3 since their disease diagnosis and up to the time of their visit. Data were stratified by study cohort
- CI confidence interval, EUR patients of European ancestry, non-EUR patients of non-European ancestry, SLE systemic lupus erythematosus
- aOdds ratio (OR) in non-European patients
- bP values calculated using Pearson’s chi-squared test
- cAdmission defined as any patient requiring hospital admission specifically for SLE in the 5 years prior to and including the date of their clinic visit at which the blood sample was taken
- dPatients treated with biologic drugs at any time since their disease diagnosis
